Inter- and intrapatient variability in etoposide kinetics with oral and intravenous drug administration.

The objective of this study was to accurately determine the within- and between-patient variability in etoposide pharmacokinetics for i.v. and p.

Bioavailability of low-dose oral etoposide.

Purpose: To determine the bioavailability of oral etoposide capsules administered at doses of 100 mg and 400 mg.

Patients And Methods: The bioavailability of oral etoposide was determined by measuring the area under the etoposide plasma concentration versus time curve (AUC) following intravenous (IV) etoposide administration and comparing that value to the AUC achieved following an oral dose administered 1 day later to the same patient. The bioavailability of a 100-mg oral dose of etoposide was measured on 16 occasions in 11 patients.

Somatostatin analogue phase I trials in neuroendocrine neoplasms.

To further investigate the antineoplastic efficacy and safety of somatostatin analogues, 2 trials were performed. Octreotide, SMS 201-995 (Sandostatin), was escalated in doses ranging from 1,500 micrograms to 6,000 micrograms daily in 14 patients with carcinoid. Somatuline, (BIM 23014C, Angiopeptin, Lanreotide) was given in doses ranging from 2,250 micrograms to 9,000 micrograms daily to 13 neuroendocrine patients (6 carcinoid, 2 atypical carcinoid, 3 pancreatic islet cell and 2 small cell lung cancer patients).